🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Christelle de la Fouchardière

Institut Paoli-Calmettes

ORCID: 0000-0003-2291-5693

Decision SciencesMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial”.

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)01366-1

N/A

5.4DataRank · unranked

454 citations

Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle de la Fouchardière +14 more

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

New England Journal of Medicine(2011)10.1056/nejmoa1011923

N/A

1.3DataRank · unranked

6381 citations

Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Yves Bécouarn +21 more

PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon

Cancer Discovery(2022)10.1158/2159-8290.cd-21-0521

N/A

0DataRank · unranked

79 citations

Ivan Bièche, Éric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Lucas Michon +51 more